Document is current
Any future updates will be listed below
-
Authors
Marshall, Robert
Abu-Rumeileh, Samir
Habeck, Lisa
Steinacker, Petra
Foschi, Matteo
Wohlfahrt, Kai
Schwesig, René
Riepenhof, Helge
Droste, Jan-Niklas
Barba, Lorenzo
Otto, Markus https://orcid.org/0000-0003-4273-4267
-
Funding
Funding for this research was provided by:
Martin-Luther-University Halle-Wittenberg (JCS24/02, CS22/06)
Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch (01ED2008A)
Bundesministerium für Bildung und Forschung (FTLDc 01GI1007A)
EU Moodmarker program (01EW2008)
Deutsche Forschungsgemeinschaft (SFB1279)
Baden-Württemberg Stiftung (D.3830)
Boehringer Ingelheim Ulm University BioCenter (D.5009)
Martin-Luther-Universität Halle-Wittenberg
- License Information
-
More Information
Article History
Received: 26 March 2025
Revised: 12 May 2025
Accepted: 16 May 2025
First Online: 13 June 2025
Declarations
:
: MO gave scientific advice for Fujirebio, Roche, Biogen, and Axon. The other authors have nothing to declare.
